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Alzheimer’s disease (AD) is increasing in prevalence with the aging population. Deposition of amyloid-β (Aβ)i nt h eb r a i no fA D
patients is a hallmark of the disease and is associated with increased microglial numbers and activation state. The interaction of
microglia with Aβ appears to play a dichotomous role in AD pathogenesis. On one hand, microglia can phagocytose and clear Aβ,
but binding of microglia to Aβ also increases their ability to produce inﬂammatory cytokines, chemokines, and neurotoxic reactive
oxygen species (ROS). Scavenger receptors, a group of evolutionally conserved proteins expressed on the surface of microglia act as
receptors for Aβ. Of particular interest are SCARA-1 (scavenger receptor A-1), CD36, and RAGE (receptor for advanced glycation
end products). SCARA-1 appears to be involved in the clearance of Aβ, while CD36 and RAGE are involved in activation of
m i c r o g l i ab yA β. In this review, we discuss the roles of various scavenger receptors in the interaction of microglia with Aβ and
propose that these receptors play complementary, nonredundant functions in the development of AD pathology. We also discuss
potential therapeutic applications for these receptors in AD.
1.MicrogliaandAlzheimer’sDiseasePathology
Alzheimer’s disease (AD) is a devastating neurological con-
dition characterized by increasing memory loss, inability
to perform daily tasks, and eventually dementia. This fatal
condition currently has no cure, and by 2050, 13 million
people in the United States are projected to be aﬀected by
the disease [1]. AD brains show deposition of the protein
amyloid-β(Aβ)insenileplaques[2],thisproteinisproduced
by cleavage of APP (amyloid precursor protein), by the
enzymes β-secretase and γ-secretase [3]. Aβ accumulates in
soluble form and also undergoes conformational changes to
become ﬁbrillar, microglia interact with both soluble and
ﬁbrillar forms of Aβ [4–6].
In addition to Aβ accumulation during the development
ofAD,tauproteinalsoaccumulatesinneuroﬁbrillarytangles
(NFT) in cell bodies of neurons [7] and apical dendrites
[8]. Tau is a microtubule-associated protein that segregates
into axons and stabilizes their microtubules. In AD, tau
dissociates from the microtubules and begins to accumulate
in the somatodendritic compartment of the axon, a process
which is not fully understood [9]. Tau contains a high num-
ber of phosphorylation sites and upon phosphorylation dis-
sociates from the microtubules, as observed in AD [10]. Tau
protein then undergoes conformational changes which form
ﬁbrils [11]. NFT could possibly activate microglia which
may prove deleterious for the surrounding neurons and con-
tribute to disease progression, however, little is known about
the NFT mechanism of action [12].
Microglia are the major phagocytic cell of the brain and
become activated upon encountering Aβ [6]a n dc a nr e l e a s e
chemokines and cytokines into their environment [13].
MicrogliaarebelievedtoinitiallyclearAβ deposits,butasthe
disease progresses, they produce proinﬂammatory cytokines,
chemokines,andreactiveoxygenspecies(ROS)andlosetheir
ability to clear Aβ [14], and despite increased numbers of
microgliaintheADbrain,theplaquescontinuetoincreasein
size and number [15]. This inﬂammatory environment ulti-
mately becomes toxic to the surrounding neurons, resulting
in neuronal degeneration and disease progression [16].2 International Journal of Alzheimer’s Disease
Scavenger receptors bind many ligands with high aﬃnity,
including Aβ [4, 17], and have been shown to be expressed
on microglia surrounding Aβ plaques in the brain [18].
This review will focus on the role of scavenger receptors in
AD development and discuss eﬀorts to examine scavenger
receptors as targets for therapy.
2. What AreScavenger Receptors (SRs)?
Several families of pattern recognition receptors (PRR) have
been identiﬁed including the well-deﬁned and extensively
studied Toll-like and Nod-like receptors (TLR and NLRs).
In addition to these proteins, the scavenger receptor (SR)
family represents another major class of PRR. SRs were ﬁrst
described in 1979 by Brown and Goldstein as macrophage
receptors that mediate endocytosis of modiﬁed low-density
lipoprotein (LDL) leading to foam cell formation and were
shown to play a role in the pathogenesis of atherosclerosis
[19, 20]. Since then, the deﬁnition of SRs has been broad-
ened: SRs are deﬁned as a family of molecules that share the
ability to bind polyanionic ligands. This simple deﬁnition
belies the importance of SRs as PRRs-SRs are archetypal
multifunctional receptors, often able to bind ligands of both
pathogen and self-origin. These receptors are teleologically
ancient pathogen receptors, emphasizing their important
role in host defense. However, while the critical roles SRs
play in atherosclerosis and host defense against a variety
of pathogens is well characterized, the exact role of these
receptors in the pathogenesis of neurodegenerative disorders
including AD is not clearly understood.
3. Classiﬁcationof SRs
SRs are structurally unrelated membrane receptors that
are highly expressed by phagocytes such as macrophages,
dendritic cells, and microglia, and also found on selected
endothelial cells (Figure 1). To date, the SRs family has been
classiﬁedinto6classesbutadditionalmembersofthisfamily,
like CD163, RAGE, and SR-PSOX (scavenger receptor that
binds phosphatidylserine and oxidized lipoprotein) remain
unclassiﬁed. SRs are deﬁned by their common ability to
bind polyanionic ligands with high aﬃnity and have broad
speciﬁcity. SRs cooperate with the other innate immune
PRRs like the TLRs to deﬁne pathogen-speciﬁc responses
[21]. However, unlike the TLRs and NLRs, SRs facilitate
ligand uptake by phagocytosis and endocytosis [22].
4. ClassA Scavenger Receptors (SCARA)
SCARA are required for host defense against several bac-
terial and viral pathogens: SCARA-1 is an arrangement of
three coiled extracellular regions with cysteine-rich domains
connected to the plasma membrane by a long ﬁbrous stalk
composed of an alpha-helical coiled coil and a collagen rich
triple helix which is believed to bind ligands through the
collagen-like domain [23–25]( Figure 1). SCARA-1 exem-
plify this family of multiligand receptors, in addition to
binding to modiﬁed lipoproteins, lipopolysaccharide (LPS),
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Figure 1: Structural diversity of the scavenger receptors. SCARA
have a collagen-like domain believed to be their ligand-binding
domain. CD68 has a mucin-like domain; LOX-1(oxidized-low
density lipoprotein (lectin-like) receptor-1) (SCARE) has a C-type
lectin domain and binds oxidized LDL. SCARF (scavenger receptor
class F) has multiple extracellular EGF-like repeats.
[26] and lipoteichoic acid (LTA) [27, 28], we and others
have shown that SCARA-1/2 also bind ﬁbrillar β-amyloid
and advanced glycosylation end products (AGEs) [4, 25].
SCARA-1/2 mediate phagocytosis of infectious organisms
like Staphylococcus aureus [28]a n dNeisseria meningitides
[29] and also mediate clearance of apoptotic thymocytes
[30]. Because of their broad ligand speciﬁcity, SCARA-1/2
contribute to resistance to gram-positive and gram-negative
microbial infections and some viral infections in vivo, and
SCARA-1/2 null mice succumb to S. aureus, and Herpes
simplex infections faster than normal mice [28, 31]. In
addition, SCARA-1/2 null mice also demonstrate increased
susceptibilitytoLPS-inducedshock,[32]suggestingapot en-
tial role in regulating the endotoxin response.
4.1. SCARA Role in Alzheimer’s Disease. Murine microglia
bind and phagocytose Aβ via SCARA1. Studies using a
transgenic mouse model of AD expressing the human form
of Aβ, and developing Aβ plaques in the brain over time
[33] showed an increased level of SCARA-1 on microglia
around Aβ plaques [34]. Microglia isolated from human
brains were also able to bind to and ingest Aβ via SCARA-
1[ 35]. Additional evidence that SCARA-1 is an impor-
tant phagocytic receptor for Aβ comes from studies using
microglia from SCARA-1 knock-out mice. SCARA-1 knock-
out microglia isolated from these animals showed a 60%
decrease in the ability to take up amyloid-β compared with
wild-type cells [36]. These results suggest that in addition to
SCARA-1, other receptors may be involved in clearance of
Aβ by microglia. Since SCARA-1 is involved in clearance of
Aβ, from a therapeutic standpoint, it may be beneﬁcial to
upregulate expression of this receptor on microglia thereby
increasing the ability of these cells to clear Aβ.
Another SCARA that has been shown to interact with
Aβ is the macrophage scavenger receptor with collagenous
structure (MARCO). MARCO is a SCARA family memberInternational Journal of Alzheimer’s Disease 3
but is encoded by a distinct gene from SCARA-1/2. Impor-
tantly, MARCO and SCARA1/2 have both common and
distinct ligands [37, 38]. MARCO is expressed on cultured
neonatal rat microglia and is also a receptor for Aβ [39].
It is not known if MARCO is expressed in microglia in the
AD brain. By coimmunoprecipitation, MARCO has been
shown to form a complex with formyl peptide-receptor-like
1 (FPRL1) upon encountering Aβ. Intracellular signaling via
ERK 1/2 and inhibition of cAMP is then initiated through
FPRL1whichmayplayapartindecreasingtheinﬂammatory
response mediated through MARCO in microglia [40].
5. ClassB Scavenger Receptors(SCARB)
SCARB are also important in the innate host response to
bacterial and fungal pathogens. The B class receptors are
characterized by the presence of membrane-spanning N and
C termini and a large extracellular loop [41]( Figure 1).
CD36 (SCARB-2), the ﬁrst classiﬁed SCARB was initially
identiﬁed as a receptor for thrombospondin [42]a n d
for malaria parasitized erythrocytes [43]. Endemann and
colleagues subsequently identiﬁed CD36 as the “second”
modiﬁed lipoprotein receptor [44], the ﬁrst receptor being
SCARA-1/2. By virtue of their ability to bind HDL and act
as fatty acid transporters, CD36 and SCARB-1 play major
roles in cholesterol metabolism [45–47]. CD36 also binds
and internalizes S. aureus a n di sr e q u i r e df o rp r o t e c t i o n
against this pathogen [21] .R e c e n t l y ,w eh a v eu n c o v e r e da
novel role for CD36 as a receptor for β-glucan [48]. We also
foundthatCD36anditsC.elegansorthologplayamajorrole
in host defense to opportunistic infections with pathogenic
y e a s ts u c ha sCandida albicans and Cryptococcus neoformans.
Interestingly, SCARB-1 act as a coreceptor for the hepatitis C
virus and may play a role in viral pathogenesis of hepatitis
C[ 49, 50]. In addition to binding to microbial ligands,
CD36 binds several modiﬁed “self” antigens including AGE-
modiﬁed proteins involved in the pathogenesis of vascular
complications of diabetes [51].
5.1. SCARB Role in Alzheimer’s Disease. Scavenger receptor
B1 (SCARB-1) is a receptor for Aβ on microglia. A study
by Husemann et al. [52] proposed that SCARB-1 is devel-
opmentally regulated and was not found on microglia in
adult human brain and was only expressed on astrocytes.
I nam o u s em o d e lo fA D ,ar e d u c t i o ni nS C A R B - 1p r o t e i n
expression increased Aβ plaque deposition had no eﬀect
on microglial accumulation around Aβ plaques and in fact
worsened cognitive defects in learning and memory [53].
CD36/SCARB-2 is also expressed on microglia and a
receptor for amyloid-β [54]. Intracellular signaling through
CD36 is activated upon Aβ binding and activates microglia
to produce cytokines and chemokines that induce microglial
migration [55]. CD36 knock-out microglia have less Aβ-
mediated activation and reduced chemokines and cytokine
production compared with wild-type cells. Injection of Aβ
into CD36 knock-out mouse brains induced less accumula-
tion of microglia compared with wild-type brains, demon-
strating an important role for CD36 in the inﬂammatory
response to Aβ [54]. Microglial CD36 signals upon Aβ
engagement via the Src family members Fyn and Lyn and by
activation of mitogen-activated protein kinase (MAPK) and
subsequent chemokine and ROS production [56].
Further investigation of the signaling properties of CD36
has recently been shown to be intimately involved with two
toll-like receptors TLR-4 and TLR-6. Upon Aβ engagement,
CD36 forms a heterodimeric complex with TLR-4 and TLR-
6 on microglia resulting in ROS production, and an increase
in IL-β mRNA, indicative of inﬂammasome activation [5].
From a therapeutic standpoint, it may be advantageous
to inhibit the ability of CD36 to signal when bound to Aβ,
and thus prevent the release of chemokines and ROS by
microglia that are deleterious to the surrounding neurons.
We recently undertook a high-content screen to identify
small molecule inhibitors of CD36. Screening of an FDA-
approved compound library discovered ursolic acid to be an
inhibitor of CD36 binding to Aβ. In addition, ursolic acid
also inhibited Aβ-mediated ROS production in microglia
without eﬀecting microglial ability to phagocytose Aβ
[57].
6. ClassC Scavenger Receptors (SCARC)
SCARC-1 was identiﬁed in Drosophila but no mammalian
ortholog for this receptor has yet been discovered. SCARC-
1 is involved in phagocytosis of Gram-negative and Gram-
positive bacteria but not yeast [58, 59]. Intriguingly, SCARC-
1 also mediates uptake of dsRNA [59]. Since no mammalian
ortholog for SCARC has been identiﬁed, it remains to be
determined if this class of SR plays any role(s) in mammalian
physiology or disease pathogenesis.
7. ClassD Scavenger Receptors (SCARD)
TheclassDSRsarecharacterizedbythepresenceofamucin-
like extracellular domain (Figure 1). The best characterized
SCARD is CD68 (also known as macrosialin), which is
expressed by macrophages, dendritic cells microglia, and
osteoclasts [60, 61] For this reason, CD68 has been used
for many years as a histological marker for these cells. It is
found mainly intracellularly in late endosomes but cell
surfaceexpressionincreasesfollowingactivation[62].CD68/
macrosialin plays a minor role in the binding and uptake
of oxidized lipoproteins and apoptotic cells by macrophages
[63].
7.1. Role of SCARD in Alzheimer’s Disease. Studies investi-
gating a role of SCARD in AD have been mostly descriptive.
Immunizing human subjects with AD with Aβ 1–42 caused a
reduction in plaques and an upregulation of CD68 expressed
on microglia [64]. However in two longer surviving subjects,
eventhoughAβplaqueswerecleared,theexpressionofCD68
was found to be lower than in nonimmunized AD brains
[65]. No studies to date investigated whether this class of SRs
is mechanistically involved in CNS disorders including AD.4 International Journal of Alzheimer’s Disease
8. ClassE Scavenger Receptors (SCARE)
Lectin-like oxidized LDL receptor (LOX-1) was the ﬁrst scav-
enger receptor with a C-type lectin-like domain (Figure 1)
to be identiﬁed. LOX-1 was initially cloned from endothelial
cells and appears to play a role in atherosclerosis [66].
LOX-1 is expressed on freshly isolated human monocytes
[67], LOX-1 decreases with monocyte diﬀerentiation into
macrophages. LOX-1 binds oxidized LDL [66] and has also
been implicated in the transport of β-amyloid across the
blood brain barrier [68, 69]. In addition, LOX-1 binds gram
positiveandgramnegativebacteria,althoughitsexactrolein
the innate immune response to these pathogens is unknown
[70]. It is not known if LOX-1 is expressed on microglia.
9. ClassF Scavenger Receptors-SCARF
SCARFs are characterized by the presence of multiple
extracellular epidermal growth factor-like repeats (Figure 1).
The ﬁrst SCARF was identiﬁed as an endothelial receptor for
modiﬁed LDL, termed SREC [71]. In addition to binding
modiﬁed LDL, SCARFs are receptors for heat shock proteins
[72] and calreticulin which is involved in traﬃcking asso-
ciated peptides into the major histocompatibility complex
class I cross-presentation pathway of antigen-presenting cells
[73]. We found that SCARF-1 is expressed on macrophages,
and that SCARF-1 plays an important role in binding of the
pathogenic yeasts Candida albicans and Cryptococcus neofor-
mans. SCARF appears to be conserved through evolution.
CED-1, a C. elegans ortholog of SCARF also appears to
play a major role in the innate worm immune response to
pathogenic yeast, and CED-1-deﬁcient mutant worms have a
dramatic increase in their susceptibility to these infections
[48]. Interestingly, CED-1 also binds to cell corpses [74].
Similarly, related families of molecules have been identiﬁed
inDrosophilamelanogaster wheretheyalsocontributetohost
defense [75].
9.1. Role of SCARF in Alzheimer’s Disease. It is not known
if SCARF1 is expressed in the brain and/or involved in
AD pathogenesis. MEGF10 (multiple EGF-like domains-10),
also a member of the SCARF family, has recently been
shown to be a receptor for Aβ [76]. MEGF10 is a type
1 transmembrane protein containing 17 EGF-like domains
in the extracellular portion (Figure 1)[ 77]. MEGF10 is
expressed in the brain of a transgenic mouse model of AD
in the hippocampus and cortex region of the brain where Aβ
plaques are also found, but it is unknown whether MEGF10
is expressed on microglia [76].
10. UnclassiﬁedScavenger Receptors
10.1. RAGE. RAGE (receptor for advanced glycation end
products) is a member of the immunoglobulin superfamily
of receptors [78] expressed on endothelial cells [79]a n d
microgliawhichiscapableofbindingmanyligandsincluding
Aβ [80], AGEs (advanced glycation end products) and
S100 protein [81]. Ligand binding to RAGE induces many
intracellular signaling pathways such as Ras-extracellular
signal-regulated kinase 1/2 (ERK1/2) [82], Cdc42/Race [83]
stress-activated protein kinase/c-Jun-NH2-terminal kinase
(SAPK/JNK), and p38 mitogen-activated protein (MAP)
kinase pathways [84] that activate transcription factors,
for example, NFκB[ 85], cAMP response element-binding
(CREB) protein [82], or (STAT3), a member of the signal
transducers and activators of transcription family [86].
RAGE activation through ligand binding induces a positive
signalingfeedbackloopcausingsustainedactivationofNFκB
and a chronic state of inﬂammation [87].
10.1.1. Role of RAGE in Alzheimer’s Disease. RAGE expressed
on endothelial cells has previously been shown to play a
role transporting Aβ into the brain [88], and also increasing
the diapedesis of monocytes across the blood- brain barrier
through RAGE-mediated signaling [89].
RAGE is expressed in higher levels on neurons and vas-
culatureinADbrainscomparedwithundiseasedbrains[90].
SolubleAβboundtoRAGEinducesmicroglialactivationand
chemotaxis along a concentration gradient, which may lead
to microglial accumulation around Aβ plaques. [80].
In a double-transgenic mouse model of AD (both
expressing mutated human APP and increased levels of
RAGE), Aβ deposition, and microglial activation through
NFκB were observed, providing evidence that RAGE also
functions as a signaling receptor [91]. Studies using trans-
genic mice expressing human Aβ and a dominant negative
form of RAGE showed microglial RAGE to be an essential
signaling receptor, signaling through p38 MAPK and JNK,
which leads to synaptic dysfunction through JNK-mediated
IL-β release [92].
However, more recent evidence shows that transgenic
mice expressing both the Swedish and Arctic forms of
human APP, and deﬁcient in RAGE have a decrease in Aβ
deposition and an increase in insulin degrading enzyme
(IDE), an enzyme known to cleave Aβ when compared to
mice expressing RAGE [93]. Such decrease in Aβ was found
at 6 months of age. No improvement in cognitive function
or diﬀerence in microglial recruitment to plaques was seen
in 12 months old mice. This suggests RAGE may not be
essential for microglial recruitment but could be involved in
Aβ processing in the early disease state [94].
10.2. CD163. CD163 contains nine scavenger receptor
cysteine-rich (SRCR) domains, an ancient and highly con-
served protein motif, belonging to the SRCR superfamily.
CD163 is expressed on mature tissue macrophages and has
previously been shown to be involved in the clearance of
hemoglobin-haptoglobin from the circulation [95]. Engage-
ment of macrophage CD163-induced nitric oxide, IL-1β,
and TNFα production, suggesting CD163 may be involved
in activation of macrophages at sites of inﬂammation [96].
CD163 is also involved in host defense against both gram-
positive and gram-negative bacteria, acting as an immune
sensor and mediator of inﬂammation [97]. In the brains of
patients with HIV-associated dementia, CD163 was found
to be expressed on microglia [98], and on perivascularInternational Journal of Alzheimer’s Disease 5
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Figure 2: Diverse functions of SRs in development of Alzheimer’s disease. RAGE facilitates transport of monocytes and Aβ across the
blood-brain-barrier, whereas SCARA-1 mediates internalization of Aβ by microglia. CD36 and TLR-4 and TLR-6 ligation with Aβ induces
intracellular signaling and release of ROS, chemokines and cytokines.
macrophages near the blood-brain barrier, [99] and CD163
is considered a marker for perivascular macrophages. How-
ever it is unknown whether CD163 is involved in the patho-
genesis of AD.
10.3. SR-PSOX. Scavenger receptor that binds phosphatidyl-
serine and oxidized lipids (SR-PSOX), also known as
CXCL16,isaclassHSRthatcanbebothamembrane-bound
and soluble protein. SR-PSOX is expressed on dendritic
cells, and on monocyte-derived macrophages surrounding
atherosclerotic plaques but not on smooth muscle cells or
endothelial cells [100]. The membrane-bound form is com-
posed of type I transmembrane glycoprotein, consisting of
CXCchemokine,mucinstalk,transmembrane,andcytoplas-
mic domains [101]. Treatment of human peripheral blood
mononuclear cells (PBMCs) with IFNγ induced increased
uptake of oxLDL and increased levels of SR-PSOX [102]. The
soluble form of SR-PSOX has been shown to ligate the T-
cell receptor CXCR6 and attracts IFNγ-producing T cells to
lymph nodes [103]. It is not known if this receptor binds Aβ
or whether it plays a role in AD pathogenesis.
11.SR andInnateImmune Signaling
A common emerging theme is that SRs are not only innate
immune recognition and phagocytic receptors but also act as
critical regulators of inﬂammatory signaling and function as
sensors for the innate immune response. The mechanism(s)
by which SRs regulate the outcome of ligand engagement is
currently unknown.
Two potential and not mutually exclusive possibilities
exist. First, SRs may facilitate ligand delivery to other PRRs,
particularly to the TLRs, which have not been shown to be
suﬃcient for cellular binding to their targets. Pertinent to
this, recent work has demonstrated that many TLRs do not
interact with their ligands on the cell surface but within
intracellular compartments such as endosomes or phago-
somes. However, the mechanisms that deliver TLR ligands
to the appropriate compartments are poorly deﬁned. One
possibility is that ligand delivery is facilitated by coreceptors
such as Dectins [104–107] and SRs. The second scenario is
that signals triggered directly from the SRs combine with
those from other PRRsto deﬁne the ligand-speciﬁc response.
Such dichotomous cooperative role of SRs with other
PRRs is nicely illustrated by CD36. We have observed
that CD36 knockout macrophages and microglia show a
decreased response to bacterial and self-ligands including Aβ
but expression of CD36 is not by itself suﬃcient to initiate
such responses. CD36 requires the presence of TLRs to
mediatetheresponsestoitsligands[5].Thisreﬂectstworoles
for CD36 which contributes to response by both binding
the ligand and also by synergistic and cooperative signaling
with other PRRS such as TLRs. This cooperation may deﬁne
the speciﬁcity of the response to a particular ligand. Indeed,
we found that CD36/TLR2/6 respond to pathogens [108]6 International Journal of Alzheimer’s Disease
whereas CD36/TLR4/6 respond to endogenous ligands such
as β-amyloid and oxLDL. These roles for CD36 have been
mostly described in vitro. It remains to be determined if such
sophisticated ligand-receptor speciﬁcity of interaction also
occurs in vivo and whether it aﬀects diseases processes such
as AD.
12. DiverseRoles of SRs inAD
Promising evidence has shown the diversity of SRs with
regards to their functions during the development of AD.
SCARA-1 and CD36 play complementary nonredundant
roles in the interactions of microglia with Aβ. SCARA-1-
Aβ interactions are beneﬁcial and promote phagocytosis and
clearance of Aβ, whereas CD36-Aβ interactions are harmful
and together with TLR-4 and TLR-6 lead to production
of neurotoxins and proinﬂammatory molecules. This is
reminiscent of the role CD36 plays in the interaction bet-
ween macrophages and oxidized low-density lipoproteins
in atherosclerosis. Indeed, we have shown in the past that
while SCARA-1 mediates adhesion to oxidized LDL coated
surfaces, CD36 mediates macrophage activation by oxidized
LDL to produce reactive oxygen species [109]. Such diﬀer-
ential roles of SCARA-1 and CD36 may have therapeutic
implications for AD. Indeed, because of the role of SCARA-1
in Aβ clearance, drugs that upregulate SCARA-1 expression
or functions may be helpful for treatment of AD. In contrast,
drugsthatblockCD36interactionswithAβ orreduceitssur-
face expression may be helpful to stop or delay progression
of AD. Similarly, since RAGE expressed on endothelium
facilitates the transport of circulating Aβ from the blood
across the blood-brain barrier into the brain, compounds
that block Aβ-RAGE interactions may be beneﬁcial. In
addition to SCARA-1, CD36 and RAGE, and other SRs such
as MARCO, LOX-1, and MEGF-10 are also emerging as
receptors that bind Aβ and/or may have a role in the patho-
genesis of disease (Figure 2). Dissecting the complex roles of
various scavenger receptors in microglia-Aβ interactions, is
therefore, important to understand the role of microglia in
this disease and has therapeutic implications for treatment
of this devastating disorder.
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